KLRS Q3 2021 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$180M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$44,000

Operating Income

-$46M

Net Income

-$46M

EPS (Diluted)

$-16.62

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$36M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$317M

Total Liabilities

$49M

Stockholders' Equity

$267M

Cash & Equivalents

$243M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$44,000	-$18,000	-144.4%
Operating Income	-$46M	-$24M	-90.4%
Net Income	-$46M	-$24M	-92.7%